N/A N=185 Computerized Tool for Preventing Prenatal Drinking
Foetal Exposure During Pregnancy
Primary: Number of Participants Reporting Risky Alcohol Use — 99; 86; 60; 48 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 BKM120 For Triple Negative Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Phase 2 N=39 Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants
Phase 2 N=30 The Effects of RPL554 in Addition to Tiotropium in COPD Patients
Chronic Obstructive Pulmonary Disease Moderate
Primary: Peak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing — 0.477; 0.500; 0.373 Liters — p=0.0022
N/A N=96 Effects of a Single-session Implicit Theories of Personality Intervention on Early Adolescent Psychopathology
Anxiety Symptoms · Depressive Symptoms
Primary: Change in Children's Depression Inventory (CDI) From Baseline to 9-month Follow-up — 12.35; 11.76; 11.54; 11.66 scores on a scale
Phase 2 N=46 Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
Psoriasis · Plaque Psoriasis
Primary: Safety - Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs — 27; 32; 0; 0 TEAEs
Phase 1 N=50 A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
Shigellosis
Primary: Number of Subjects With Solicited Local Reaction After Any Vaccination — 8; 9; 8; 8 Participants
Phase 2 N=50 Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Participants With Dose Limiting Toxicities in the 5 Radiation Sessions in One Week Arm — 0 Participants
N/A N=4,005 Indiana University Dementia Screening Trial
Dementia · Alzheimer's Disease · Mild Cognitive Impairment
Primary: Health Related Quality of Life (HRQOL) — 0.71; 0.69; 0.69; 0.70 units on a scale
Phase 2 N=239 Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder
Primary: Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed — 25.5; 25.6; 25.5; 25.8 score on a scale
N/A N=168 Training Parents by Acceptance and Commitment Therapy for Managing Childhood Asthma Care
Childhood Asthma
Primary: Child's Total Number of Emergency Department Visits Due to Asthma Attacks Over the 6 Months Post Intervention — 0.38; 0.08 Number of visits — p=<0.05
Phase 2 N=61 A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
Rosacea
Primary: Change in Inflammatory Lesion Counts — -1.4; 2.9 Number of lesions
Phase 3 N=79 Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy
Colonoscopy
Primary: Success Rates of the Procedure — 27; 0; 4 Participants
Phase 2 N=279 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Phase 3 N=83 Pentoxifylline Treatment in Acute Pancreatitis (AP)
Acute Pancreatitis (AP) · Gallstone Pancreatitis · Alcoholic Pancreatitis
Primary: Change in C-reactive Protein (C-RP) From Admission Baseline at One Week. — 86.2; 75.8; 116.4; 127.2 mg/L — p=0.5796